drugset / Trial / NCT00339131

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

NCT00339131

Phase 1 Completed 24 enrolled Molecular Insight Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.

Timeline

Start
2006-06
Primary completion
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 131I-MIBG Protein / enzyme biologic